Medtronic’s stock could rise more than 40% from its current price of $86 to hit a high-end Wall Street target of $121 by the end of 2026, according to a Motley Fool analysis. The medical device maker’s shares have slumped over 30% in the past five years amid higher costs, supply chain issues, and competitive pressure, but its restructuring efforts are gaining traction. In fiscal 2026, revenue grew 8.4% to $36.4 billion, marking its strongest top-line growth in a decade, while analysts project earnings per share to grow at a compound annual rate of 13% through fiscal 2029. The company recently spun off its diabetes unit as MiniMed and is expanding higher-margin cardiovascular and neuroscience portfolios while integrating AI into surgical planning. Even at $121, the stock would trade at just 18 times next year’s earnings and offers a 3.3% forward dividend yield, with a potential Dividend King milestone next year if it raises its payout for the 50th consecutive year.
Medtronic PLCAnalyst projects 40% upside to $121, citing strong revenue growth and EPS growth.
MiniMed Group, Inc. Common Stock